IRVINE, Calif., Aug. 9, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat (ENT), today reported results for the second quarter 2017.
For the three months ended June 30, 2017, the Novus reported a net loss of $6.7 million or $1.32 per share.
